FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2559274756> ?p ?o ?g. }

• W2559274756 abstract "Abstract Abstract 4175 Introduction TAK-442 is a novel orally active, direct Factor Xa (fXa) inhibitor in clinical development for the prevention of venous and arterial thrombotic disorders. Currently, aspirin and clopidogrel are widely used for platelet inhibition in patients with an increased risk of atherothrombotic events, and it is highly likely that TAK-442 may provide incremental anti-thrombotic benefit when used in conjunction with either of these agents. The primary aim of this study was to evaluate the effect of TAK-442 on inhibition of platelet aggregation by aspirin or clopidogrel. Methods Healthy male and female (n=77), subjects were randomly assigned to 1 of 2 treatments groups and received either TAK-442 60 mg or placebo twice daily (BID) for 11 days, with the addition of aspirin 162 mg or clopidogrel 75 mg once daily (QD) from days 5 to 11. Pharmacokinetics were assessed for TAK-442 (days 4 and 11), aspirin/salicylic acid (day 11) and clopidogrel/carboxylic acid metabolite (day 11. Inhibition of fXa (Coatest®) was assessed on day 1 and two hours post dose on days 4 and 11. Platelet aggregation (arachidonic acid-induced for the aspirin group or ADP-induced for the clopidogrel group) was assessed on day -1 and 2 hours post dose on days 4 and 11; bleeding time was assessed on day -1 and 2 hours post dose on day 11. Results Inhibition of arachidonic acid-induced platelet aggregation by aspirin was not affected by TAK-442 (71% for aspirin + TAK-442 and 74% for aspirin + placebo) nor was there any clinically significant effect of TAK-442 treatment on the inhibition of ADP-induced platelet aggregation by clopidogrel (56% for clopidogrel + TAK-442 and 67% for clopidogrel + placebo) at 2 hours post dose on day 11. Likewise, co-administration of TAK-442 did not have a clinically significant effect on the pharmacokinetic profiles of aspirin or clopidogrel. AUC0-24 and Cmax values were increased ≤16% for clopidogrel and ≤13% for the carboxylic acid metabolite. Although aspirin AUC0-24 and Cmax were increased 2- to 3-fold with coadministration (90% confidence intervals were: 76.2% to 741.8% and 90.1% to 825.1%, respectively), the proportional exposure was very low and the variability was high; the values for the active metabolite, salicylic acid, were increased less than 20% with coadministration. TAK-442-mediated inhibition of fXa activity and prolongation of PT, and the PK profile of TAK-442, were unaffected by co-administration with aspirin or clopidogrel. Coadministration of TAK-442 resulted in modest increases in mean bleeding time compared to aspirin with placebo (aspirin + TAK-442: 558 sec vs. aspirin + placebo: 392 sec) and to clopidogrel with placebo (clopidogrel + TAK-442: 893 sec vs. clopidogrel + placebo: 829 sec). TAK-442 was well tolerated, with a low and similar frequency of mild bleeding events with or without aspirin or clopidogrel coadministration. Conclusion This study demonstrated that no clinically meaningful pharmacodynamic or pharmacokinetic interactions were observed when TAK-442 was co-administered with aspirin or clopidogrel. Disclosures: Stringer: Takeda Global Research & Development, Inc.: Employment. Scott:Takeda Global Research & Development, Inc.: Employment. Kupfer:Takeda Global Research & Development, Inc.: Employment. Cao:Takeda Global Research & Development, Inc.: Employment. Kawamura:Takeda Global Research & Development, Inc.: Employment." @default.
• W2559274756 created "2016-12-08" @default.
• W2559274756 creator A5022359679 @default.
• W2559274756 creator A5024584543 @default.
• W2559274756 creator A5067566652 @default.
• W2559274756 creator A5088202627 @default.
• W2559274756 creator A5090582633 @default.
• W2559274756 date "2009-11-20" @default.
• W2559274756 modified "2023-09-30" @default.
• W2559274756 title "Absence of Pharmacodynamic or Pharmacokinetic Interactions When TAK-442, An Oral, Direct Factor Xa Inhibitor, Is Coadministered with Aspirin or Clopidogrel." @default.
• W2559274756 doi "https://doi.org/10.1182/blood.v114.22.4175.4175" @default.
• W2559274756 hasPublicationYear "2009" @default.
• W2559274756 type Work @default.
• W2559274756 sameAs 2559274756 @default.
• W2559274756 citedByCount "3" @default.
• W2559274756 crossrefType "journal-article" @default.
• W2559274756 hasAuthorship W2559274756A5022359679 @default.
• W2559274756 hasAuthorship W2559274756A5024584543 @default.
• W2559274756 hasAuthorship W2559274756A5067566652 @default.
• W2559274756 hasAuthorship W2559274756A5088202627 @default.
• W2559274756 hasAuthorship W2559274756A5090582633 @default.
• W2559274756 hasConcept C111113717 @default.
• W2559274756 hasConcept C112705442 @default.
• W2559274756 hasConcept C126322002 @default.
• W2559274756 hasConcept C149151106 @default.
• W2559274756 hasConcept C181199279 @default.
• W2559274756 hasConcept C185592680 @default.
• W2559274756 hasConcept C2777628954 @default.
• W2559274756 hasConcept C2777849778 @default.
• W2559274756 hasConcept C2778078955 @default.
• W2559274756 hasConcept C2779216453 @default.
• W2559274756 hasConcept C2993802102 @default.
• W2559274756 hasConcept C35294091 @default.
• W2559274756 hasConcept C42219234 @default.
• W2559274756 hasConcept C55493867 @default.
• W2559274756 hasConcept C71924100 @default.
• W2559274756 hasConcept C89560881 @default.
• W2559274756 hasConcept C98274493 @default.
• W2559274756 hasConceptScore W2559274756C111113717 @default.
• W2559274756 hasConceptScore W2559274756C112705442 @default.
• W2559274756 hasConceptScore W2559274756C126322002 @default.
• W2559274756 hasConceptScore W2559274756C149151106 @default.
• W2559274756 hasConceptScore W2559274756C181199279 @default.
• W2559274756 hasConceptScore W2559274756C185592680 @default.
• W2559274756 hasConceptScore W2559274756C2777628954 @default.
• W2559274756 hasConceptScore W2559274756C2777849778 @default.
• W2559274756 hasConceptScore W2559274756C2778078955 @default.
• W2559274756 hasConceptScore W2559274756C2779216453 @default.
• W2559274756 hasConceptScore W2559274756C2993802102 @default.
• W2559274756 hasConceptScore W2559274756C35294091 @default.
• W2559274756 hasConceptScore W2559274756C42219234 @default.
• W2559274756 hasConceptScore W2559274756C55493867 @default.
• W2559274756 hasConceptScore W2559274756C71924100 @default.
• W2559274756 hasConceptScore W2559274756C89560881 @default.
• W2559274756 hasConceptScore W2559274756C98274493 @default.
• W2559274756 hasLocation W25592747561 @default.
• W2559274756 hasOpenAccess W2559274756 @default.
• W2559274756 hasPrimaryLocation W25592747561 @default.
• W2559274756 hasRelatedWork W1602326000 @default.
• W2559274756 hasRelatedWork W1620586541 @default.
• W2559274756 hasRelatedWork W1694855869 @default.
• W2559274756 hasRelatedWork W196615512 @default.
• W2559274756 hasRelatedWork W2001287599 @default.
• W2559274756 hasRelatedWork W2023394373 @default.
• W2559274756 hasRelatedWork W2051297375 @default.
• W2559274756 hasRelatedWork W2079293886 @default.
• W2559274756 hasRelatedWork W2348245350 @default.
• W2559274756 hasRelatedWork W2353611822 @default.
• W2559274756 hasRelatedWork W2360342532 @default.
• W2559274756 hasRelatedWork W2368367966 @default.
• W2559274756 hasRelatedWork W2388618958 @default.
• W2559274756 hasRelatedWork W2391904841 @default.
• W2559274756 hasRelatedWork W2411157459 @default.
• W2559274756 hasRelatedWork W2481299576 @default.
• W2559274756 hasRelatedWork W2570814234 @default.
• W2559274756 hasRelatedWork W2601163177 @default.
• W2559274756 hasRelatedWork W3092153947 @default.
• W2559274756 hasRelatedWork W2187430490 @default.
• W2559274756 isParatext "false" @default.
• W2559274756 isRetracted "false" @default.
• W2559274756 magId "2559274756" @default.
• W2559274756 workType "article" @default.